Menu
Oncoguard® Liver Logo
  • PROVIDERS
    • Overview
    • The Oncoguard® Liver test
      • Clinical Performance
      • Scientific Rigor
      • Adding to the Workflow
      • Orders & Results
      • Insurance & Billing
    • Patient engagement program
    • About Us
    • Faqs
  • Patients
    • Liver Disease
      • Risk Factors
      • Detection & Monitoring
    • The Oncoguard® Liver Solution
      • The Oncoguard® Liver Test
      • Support
    • About Us
    • FAQs
  • EDUCATION
  • Resources
    • Ordering Information
    • Order Supplies
    • Forms
    • Specimen Collection
    • Implementation Guide
    • EpicCare® Link™
  • Contact US

Posts in: Featured

  • Patient reviewing test documentation with a healthcare provider.
    Featured
    From inception to practice— new insights from the development of a high-performance liquid biopsy test for the detection of early-stage HCC
  • Healthcare provider reviewing information on a tablet with an older male patient in a medical office setting.
    Featured
    HCC surveillance: common goals, collective impact
  • Healthcare provider reviewing information on a tablet with an older female patient during an office visit.
    Featured
    Evaluating an ALTernative to UltraSound: the ALTUS study for the surveillance of HCC
  • Masked healthcare provider reviewing information on a tablet with a masked patient during an office visit.
    Featured
    The COVID-19 pandemic reveals an opportunity to optimize the surveillance of HCC
  • Female doctor speaking to a patient.
    Featured
    Hepatocellular carcinoma in the United States—HCV infection remains a threat, even as NAFLD increases
  • Illustration of two healthcare professionals examining an enlarged liver graphic with a magnifying glass, alongside a clipboard displaying a test checklist
    Featured
    Improved Surveillance Is Urgently Needed to Help Reduce the Burden of Hepatocellular Carcinoma
  • Illustration of a blood drop, a clipboard, and test tubes
    Featured
    A simple blood test may detect HCC in its early stages, potentially improving patient outcomes
  • Healthcare provider reviewing information on a tablet with an older male patient during an office visit
    Featured
    Hepatocellular carcinoma is 10 times more likely to develop in the setting of nonalcoholic steatohepatitis than in simple fatty liver disease
  • Healthcare provider performing a physical abdominal exam on a patient lying on an exam table
    Featured
    Chronic liver disease is often a precursor to hepatocellular carcinoma
  • Healthcare provider performing an ultrasound examination on a patient, illustrating an example of hepatocellular carcinoma surveillance
    Featured
    Early-stage hepatocellular carcinoma can be challenging to detect—it doesn’t have to be
  • Healthcare provider and patient reviewing information on a tablet in a medical office setting
    Featured
    We can improve hepatocellular carcinoma surveillance by understanding how risk factors are changing
  • Illustration of researchers pouring liquid into test tubes and examining a large liver graphic
    Featured
    Hepatocellular carcinoma has a high mortality rate—Improved surveillance may help reduce it
Exact Sciences Logo

Exact Sciences Corporation
5505 Endeavor Lane
Madison, WI 53719
Contact Us

Quick Links

  • About Exact Sciences
  • Licensing & Accreditations
  • Terms of Use
  • Privacy Policy
  • HIPAA Notice
  • Your Privacy Choices

Follow us on

  • Facebook
  • Twitter
  • LinkedIn

The Oncoguard Liver test was developed, and the performance characteristics validated by Genomic Health, Inc., a wholly-owned subsidiary of Abbott following College of American Pathologists (CAP) and Clinical Laboratory Improvement Amendments (CLIA) regulations. The Oncoguard Liver test is performed at the Genomic Health Redwood City clinical laboratory. This laboratory is accredited by CAP, certified under CLIA regulations, and qualified to perform high-complexity clinical laboratory testing. This test has not been cleared or approved by the US Food and Drug Administration.

Oncoguard is a registered trademark of the Abbott group of companies. Epic and EpicCare Link are trademarks of Epic Systems Corporation. All third-party marks—® and ™—are the property of their respective owners.

© 2026 Abbott. All rights reserved.